Fig. 1From: Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanomaTreatment sequences. *BSC = best support care; A, B, C, and D represented 4 treatment strategies in the modelBack to article page